A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma

  • Patil, Sushrut (Primary Chief Investigator (PCI))
  • Kennedy, Nola (Project Manager)
  • Sungala, Nagendraprasad (Chief Investigator (CI))
  • Cochrane, Tara (Chief Investigator (CI))
  • Renwick, William (Chief Investigator (CI))
  • Badoux, Xavier C. (Chief Investigator (CI))
  • Chong, Geoffrey (Chief Investigator (CI))
  • Leahy, Michael (Chief Investigator (CI))
  • Lee, Denise (Chief Investigator (CI))
  • Giri, Pratyush (Chief Investigator (CI))
  • Presgrave, Peter (Chief Investigator (CI))
  • Johnston, Anna M. (Chief Investigator (CI))
  • Lee, Hui Peng (Chief Investigator (CI))

Project: Research

Project Details

Effective start/end date25/06/2125/06/21


  • Lymphoma
  • Malignant Haematology
  • Clinical trial